Tashkandi E
Cancer Manag Res. 2025; 17:419-428.
PMID: 40046653
PMC: 11881765.
DOI: 10.2147/CMAR.S506423.
Zhao M, Hu X, Zhuang P, Zeng A, Yu Y, Chen Z
J Bone Oncol. 2025; 51:100661.
PMID: 39995685
PMC: 11848780.
DOI: 10.1016/j.jbo.2025.100661.
Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X
Signal Transduct Target Ther. 2025; 10(1):57.
PMID: 39979279
PMC: 11842613.
DOI: 10.1038/s41392-025-02148-4.
Roberts J
BMJ Oncol. 2025; 3(1):e000559.
PMID: 39886128
PMC: 11347677.
DOI: 10.1136/bmjonc-2024-000559.
Ye C, Zhao B, Leslie W, Ruiz J, Zhao H, Abdel-Wahab N
BMJ Oncol. 2025; 3(1):e000398.
PMID: 39886118
PMC: 11347678.
DOI: 10.1136/bmjonc-2024-000398.
Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types.
Tamiya H, Nishino K, Kato Y, Nakahashi-Kato R, Kosuga-Tsujimoto Y, Kinoshita S
Curr Oncol. 2025; 32(1).
PMID: 39851958
PMC: 11764064.
DOI: 10.3390/curroncol32010042.
Computed tomography Hounsfield unit values as a treatment response indicator for spinal metastatic lesions in patients with non-small-cell lung cancer: a retrospective study in Japan.
Taniwaki H, Dohzono S, Sasaoka R, Takamatsu K, Hoshino M, Nakamura H
Asian Spine J. 2025; 19(1):46-53.
PMID: 39829178
PMC: 11895105.
DOI: 10.31616/asj.2024.0334.
Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.
Bertoldo F, Eller-Vainicher C, Fusco V, Mauceri R, Pepe J, Bedogni A
J Bone Oncol. 2025; 50():100656.
PMID: 39807373
PMC: 11728904.
DOI: 10.1016/j.jbo.2024.100656.
[Influencing fracture healing by specific osteoporosis medications].
Stumpf U, Schmidmaier R, Taipaleenmaki H, Bocker W, Kurth A, Hesse E
Z Rheumatol. 2025; 84(2):107-112.
PMID: 39806104
DOI: 10.1007/s00393-024-01610-y.
Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.
Ismuha R, Ritawidya R, Daruwati I, Muchtaridi M
Molecules. 2025; 29(24.
PMID: 39770150
PMC: 11679579.
DOI: 10.3390/molecules29246062.
The Role of Transarterial Embolization Plus Radiotherapy Compared to Radiotherapy or Transarterial Embolization Alone in the Management of Painful Bone Metastases: Results of a Systematic Review.
Vizzuso A, Renzulli M, Lancellotta V, Posa A, Cornacchione P, Fionda B
Cancers (Basel). 2025; 16(24.
PMID: 39766082
PMC: 11674161.
DOI: 10.3390/cancers16244183.
Systematic Review-Based Treatment Algorithm for the Multidisciplinary Treatment of Lung Cancer Bone Metastases.
Lim A, Yoon W, Park S, Rim C
Cancers (Basel). 2025; 16(24.
PMID: 39766043
PMC: 11674356.
DOI: 10.3390/cancers16244144.
Factors Associating with Bone-Only Metastasis in Chinese Breast Cancer Patients in the Absence of Anti-Human Epidermal Growth Factor Receptor 2-Targeted Therapy.
Li Z, Chen L, Han H, Shang Y, Li Y, Jia Z
Oncol Res Treat. 2024; 48(3):112-124.
PMID: 39681104
PMC: 11878413.
DOI: 10.1159/000543137.
Denosumab combined with radiotherapy as an alternative to surgery for advanced metastatic bone lesions and pathologic fractures: a retrospective case study of 38 patients.
Farhang M, Isaksson M, Wanman J, Lofvenberg R, Crnalic S
Acta Oncol. 2024; 63:932-938.
PMID: 39618030
PMC: 11626079.
DOI: 10.2340/1651-226X.2024.40977.
[F]FDG PET/CT performs better than CT in determining the bone biopsy site : randomized controlled clinical trial.
Chang Y, Gu Y, Ruan S, Xu S, Sun J, Jiang Z
Cancer Imaging. 2024; 24(1):160.
PMID: 39582078
PMC: 11587546.
DOI: 10.1186/s40644-024-00804-6.
Unveiling the Link Between Breast Cancer Treatment and Osteoporosis: Implications for Anticancer Therapy and Bone Health.
Goel B, Virmani T, Jain V, Kumar G, Sharma A, Al Noman A
Biomed Res Int. 2024; 2024:5594542.
PMID: 39574432
PMC: 11581800.
DOI: 10.1155/2024/5594542.
Aromatase inhibitors and fracture prevention - do 2017 guidelines work in real world?.
Mirza A, Naing Z, Khonsari P, Khan H, Abbas A, Nisar M
BJC Rep. 2024; 2(1):36.
PMID: 39516675
PMC: 11524078.
DOI: 10.1038/s44276-024-00059-5.
New insights into non-small cell lung cancer bone metastasis: mechanisms and therapies.
Xue M, Ma L, Zhang P, Yang H, Wang Z
Int J Biol Sci. 2024; 20(14):5747-5763.
PMID: 39494330
PMC: 11528464.
DOI: 10.7150/ijbs.100960.
Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases.
Mabrut E, Mainbourg S, Peron J, Maillet D, Dalle S, Fontaine Delaruelle C
J Bone Oncol. 2024; 48:100634.
PMID: 39381634
PMC: 11460504.
DOI: 10.1016/j.jbo.2024.100634.
Physical therapist management and coordination of care to prevent pathological hip fracture from metastatic disease: a case report.
Manzino A, Wilson C
Front Rehabil Sci. 2024; 5:1384782.
PMID: 39363992
PMC: 11446967.
DOI: 10.3389/fresc.2024.1384782.
